Success in traveler's diarrhea jab trial

A new study published in Infection and Immunity says that an experimental vaccine against C. jejune, a major cause of traveler's diarrhea, worked to protect mice and monkeys in a clinical study and may well prove effective in humans as well.

"We are very excited about these results," says Dr. Patricia Guerry, the senior investigator. C. jejune also plays a role in other ailments, such as inflammatory bowel disease. Guerry has been working with grant money from the National Institute of Allergy and Infectious Diseases.

In particular, Guerry noted that monkeys were completely protected from diarrhea caused by C. jejune. Traveler's diarrhea is a common ailment for Americans journeying abroad, and it has inspired several development programs by biotech companies.

- read the story from Reuters

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.